Status:
COMPLETED
Pioglitazone vs. Insulin Glargine in the Treatment of Secondary Drug Failure in Type 2 Diabetes
Lead Sponsor:
Skane University Hospital
Collaborating Sponsors:
Medical Research Council
Skane County Council Research & Development Foundation
Conditions:
Type 2 Diabetes
Secondary Drug Failure
Eligibility:
All Genders
30-75 years
Phase:
PHASE4
Brief Summary
Pioglitazone and insulin glargine are equally effective in achieving glycemic control in secondary drug failure of type 2 diabetes but the mechanisms of actions are different.
Detailed Description
The present study was undertaken to assess differences in how insulin glargine vs. pioglitazone affect: * Beta-cell function as measured by proinsulin/insulin, homeostasis model assessment for insuli...
Eligibility Criteria
Inclusion
- type 2 diabetes
- inadequately controlled on 50% of maximal-dose of an insulin secretagogue and metformin
Exclusion
- heart failure (NYHA II-IV)
Key Trial Info
Start Date :
April 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2006
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT00609856
Start Date
April 1 2004
End Date
December 1 2006
Last Update
February 7 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Malmö University Hospital
Malmo, Sweden, 20502